FDA approves Cuvrior for treatment of adults with stable Wilson’s disease

Orphalan announced FDA approval of Cuvrior for the treatment of adults with stable Wilson’s disease who are de-coppered and tolerant to penicillamine, according to a company press release.Cuvrior (trientine tetrahydrochloride, Orphalan) recently demonstrated noninferiority to penicillamine by measurement of non-ceruloplasmin copper in a global, phase 3 trial; penicillamine is currently approved as a first-line treatment for Wilson’s with approximately one-third of patients developing intolerance.“As a physician, I have seen firsthand how Wilson’s disease impacts theRead More

Categories: News

Related Articles

FDA approves miniature capsule formulation of omeprazole magnesium for heartburn

The FDA has given final approval to Perrigo Co.’s miniature 20 mg delayed-release omeprazole magnesium capsules for over-the-counter treatment of frequent heartburn., according to a…

FDA approves Sun Pharmaceuticals’ generic mesalamine extended-release capsules for UC

Sun Pharmaceutical Industries received FDA approval of its abbreviated new drug application for mesalamine extended-release capsules indicated for use in ulcerative colitis, according to a…

FDA approves first treatment for eosinophilic esophagitis in the US

The FDA has granted approval for dupilumab for the treatment of eosinophilic esophagitis for adult and pediatric patients aged 12 years and older, according to…

FDA approves Imfinzi plus chemotherapy for advanced biliary tract cancer

The FDA approved durvalumab with gemcitabine and cisplatin for adults with locally advanced or metastatic biliary tract cancer.Durvalumab (Imfinzi, AstraZeneca) — a PD-L1 checkpoint inhibitor…

September 2, 2022

Q&A: FDA approval of dupilumab for eosinophilic esophagitis a ‘victory for rare diseases’

The FDA has approved the use of dupilumab for treating eosinophilic esophagitis in adults and children aged 12 years and older, making it the first…